Use the peptide within 710 days rather than the standard 28-day window, and reduce injection volume to account for partial aggregation
And as far as I'm concerned, there's no case reports or studies that would [160:09] Andrew Huberman suggest positive or negative CNS effects, central nervous system, excuse me, of BPC157 or other peptides that we've talked about that don't fall under the typical umbrella that people go to when they think about PPC 157
Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al
This metabolic safety profile makes AOD-9604 potentially suitable for individuals with metabolic syndrome or diabetes risk factors who might not tolerate traditional growth hormone therapy, though medical supervision remains appropriate
At Midi, we hear from patients everyday who have questions about the best approaches for reaching a healthy weight in perimenopause and menopause